Although U.S. health care stocks have underperformed so far this year, some small biotech companies have bucked the trend and risen amid the artificial intelligence boom, with investors focusing more on growth opportunities than current financial performance. For example, the stock price of Recursion Pharmaceuticals rose by nearly 80%, Schrödinger's stock price rose by more than 160%, RadNet rose by nearly 80%, and Exscientia rose by more than 30%. These companies have yet to generate sustained profits from their AI-related businesses, but valuations remain high as investors bet revenue will grow quickly. The application of artificial intelligence in the pharmaceutical industry has broad prospects. For example, NVIDIA's BioNeMo framework can help scientists better understand diseases and find treatments. However, some analysts believe that artificial intelligence is still just a concept for most companies, rather than a real money-making tool. What do you think? Feel free to chat in the comment area.